Bal Pharma Limited (BALPHARMA) - Total Assets

Latest as of March 2026: Rs3.76 Billion INR ≈ $40.61 Million USD

Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) holds total assets worth Rs3.76 Billion INR (≈ $40.61 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Bal Pharma Limited debt service capacity to assess how comfortably operating cash covers total debt obligations.

Bal Pharma Limited - Total Assets Trend (2006–2026)

This chart illustrates how Bal Pharma Limited's total assets have evolved over time, based on quarterly financial data. See BALPHARMA book value for net asset value and shareholders' equity analysis.

Bal Pharma Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

Bal Pharma Limited's total assets of Rs3.76 Billion consist of 69.8% current assets and 30.2% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 1.9%
Accounts Receivable Rs947.98 Million 25.2%
Inventory Rs1.16 Billion 31.0%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs134.22 Million 3.6%
Goodwill Rs38.27 Million 1.0%

Asset Composition Trend (2006–2026)

This chart illustrates how Bal Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bal Pharma Limited (BALPHARMA) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Bal Pharma Limited's current assets represent 69.8% of total assets in 2026, an increase from 66.9% in 2006.
  • Cash Position: Cash and equivalents constituted 1.9% of total assets in 2026, down from 6.0% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2006.
  • Asset Diversification: The largest asset category is inventory at 31.0% of total assets.

Bal Pharma Limited Competitors by Total Assets

Key competitors of Bal Pharma Limited based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
China CN¥2.30 Billion
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
China CN¥8.59 Billion
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
China CN¥925.41 Million
Jw Pharmac
KO:001060
Korea ₩605.27 Billion
Kamada
TA:KMDA
Israel ILA377.21 Million
Samjin Pharm
KO:005500
Korea ₩449.14 Billion

Bal Pharma Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.05 1.07 1.08
Quick Ratio 0.59 0.60 0.68
Cash Ratio 0.00 0.04 0.00
Working Capital Rs130.06 Million Rs153.72 Million Rs116.14 Million

Bal Pharma Limited - Advanced Valuation Insights

This section examines the relationship between Bal Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.67
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 11.9%
Total Assets Rs3.76 Billion
Market Capitalization $15.41 Million USD

Valuation Analysis

Below Book Valuation: The market values Bal Pharma Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Bal Pharma Limited's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Bal Pharma Limited (2006–2026)

The table below shows the annual total assets of Bal Pharma Limited from 2006 to 2026.

Year Total Assets Change
2026-03-31 Rs3.76 Billion
≈ $40.61 Million
+11.87%
2025-03-31 Rs3.36 Billion
≈ $36.30 Million
+5.06%
2024-03-31 Rs3.20 Billion
≈ $34.56 Million
+2.03%
2023-03-31 Rs3.13 Billion
≈ $33.87 Million
+20.20%
2022-03-31 Rs2.61 Billion
≈ $28.18 Million
+8.52%
2021-03-31 Rs2.40 Billion
≈ $25.96 Million
+0.71%
2020-03-31 Rs2.38 Billion
≈ $25.78 Million
-8.77%
2019-03-31 Rs2.61 Billion
≈ $28.26 Million
+3.77%
2018-03-31 Rs2.52 Billion
≈ $27.23 Million
+9.38%
2017-03-31 Rs2.30 Billion
≈ $24.90 Million
+9.09%
2016-03-31 Rs2.11 Billion
≈ $22.82 Million
+28.78%
2015-03-31 Rs1.64 Billion
≈ $17.72 Million
+5.89%
2014-03-31 Rs1.55 Billion
≈ $16.73 Million
+3.27%
2013-03-31 Rs1.50 Billion
≈ $16.20 Million
+6.14%
2012-03-31 Rs1.41 Billion
≈ $15.27 Million
+4.33%
2011-03-31 Rs1.35 Billion
≈ $14.63 Million
+8.94%
2010-03-31 Rs1.24 Billion
≈ $13.43 Million
+2.19%
2009-03-31 Rs1.22 Billion
≈ $13.14 Million
+11.66%
2008-03-31 Rs1.09 Billion
≈ $11.77 Million
+20.23%
2007-03-31 Rs905.28 Million
≈ $9.79 Million
+2.75%
2006-03-31 Rs881.03 Million
≈ $9.53 Million
--

About Bal Pharma Limited

NSE:BALPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$15.41 Million
Rs1.42 Billion INR
Market Cap Rank
#25880 Global
#1433 in India
Share Price
Rs89.49
Change (1 day)
+1.59%
52-Week Range
Rs60.42 - Rs96.44
All Time High
Rs151.23
About

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more